Skip to main content
Premium Trial:

Request an Annual Quote

Rubicon Genomics Nabs $3.5M in Series B Round

NEW YORK, Oct. 1 - Rubicon Genomics yesterday said it has secured $3.5 million in a Series B round of private-equity funding.

 

The Ann Arbor, Mich.-based company said it will use the cash to commercialize its OmniPlex technology. The round brings to $7.2 million Rubicon has pocketed since it was founded in 2000.

 

ARCH Development Partners led the round. Picking up the rear were Duchossois TECnology Partners, Sloan Ventures, and undisclosed individual investors.

 

Rubicon said OmniPlex is designed to allow researchers with a particular focus on diagnostics to amplify, archive, and analyze DNA.

 

Click here for more information.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.